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Introduction. Medication lists and structured medication counselling (SMC) including “brown bag reviews” (BBR) are important
instruments for medication safety. The aim of this study was to explore whether patients’ use of a medication list is associated with
their beliefs about theirmedicine and theirmemory of SMC.Methods.Baseline data of 344 patients enrolled into the “Polypharmacy
in Multimorbid Patients study” were analysed. Linear regression models were calculated for the “specific necessity subscale” (SNS)
and the “specific concerns subscale” (SCS) of the German “Beliefs About Medicine Questionnaire,” including self-developed
variables assessing patients’ use of a medication list, their memory of SMC, and sociodemographic data. Results. 62.8% (𝑛 = 216)
remembered an appointment for SMC and 32.0% (𝑛 = 110) BBR.The SNS correlated positively with regular receipt of a medication
list (𝛽 = 0.286, 𝑝 < 0.01) and negatively with memory of a BBR (𝛽 = −0.268; 𝑝 < 0.01).The SCS correlated positively with memory
of a BBR (𝛽 = 0.160,𝑝 = 0.02) and negatively with the comprehensiveness of themediation list (𝛽 = −0.224;𝑝 < 0.01).Conclusions.
Acomprehensivemedication listmay reduce patients’ concerns and increase the perceived necessity of theirmedication. A potential
negative impact of BBR on patients’ beliefs about their medicine should be considered and quality standards for SMC developed.
1. Introduction
As a consequence of demographic change and improved
medical treatment, the number of patients with multiple
chronic conditions and polypharmacy is constantly increas-
ing [1]. These patients frequently require complex, interdisci-
plinary care involving multiple health care professionals and
prescribers [2]. It is well known that an increasing number of
prescribed drugs are associated with a higher risk of adverse
drug reactions (ADR) [3] and hospitalisation [4, 5].
Medication errors are the most common preventable
cause for these undesired events and comprise the pre-
scribing, dispensing, and administration of the medicine
[6]. Reasons leading to medication errors are manifold
and also context-specific [7] but frequently involve patients’
nonadherence [8] and suboptimal medication management,
including the exchange about medication-related informa-
tion among health care professionals [2].
Consequently, strengthening patients’ self-management
abilities concerning their medication and improving
the exchange of medication-related data are important
approaches to increasing medication safety [9]. In health
care systems without established gate-keeping, such as
Germany, this is particularly challenging, as patients do not
have to be registered at any general practitioner and have
free access to specialist care [10]. Furthermore, there is no
established electronic system for data exchange between
the different health care providers and settings in Germany
[11]. To date, the printed, paper-based medication list
is the most important document for medication-related
information [12, 13]. However, deficits concerning the quality
and availability of these medications lists are well known.
In Germany, 25–50% of patients with long-term medica-
tion have a medication list [14]. Several studies showed that
discrepancies between the documented and actually taken
medication appear in about 75% of the cases [15–17], of
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which 25% are considered potentially harmful [18]. Due to
the lacking standardisation of the medication lists, important
information is frequently lacking or—in case of handwritten
medication lists—not readable [19].
An important instrument to increase the sufficiency and
correctness of medication lists is a so-called “brown bag
review,” an inventory of the medication actually taken by
the patient based on the medication packages the patient
is using [20]. According to a German guideline on mul-
timedication [21], this review should be part of a specific
appointment for “structured medication counselling” (SMC)
at the general practitioner’s clinic. During SMCan assessment
of (undesired) effects of the medication and possible reasons
for nonadherence, such as application problems or attitudes
and concerns towards the medication, should be broached
[22].
Within the “Polypharmacy inMultimorbid Patients Study
(PomP)” a tailored intervention to implement SMC into pri-
mary care practices and to increase the quality and availability
of medication lists has been developed and evaluated in a
randomised controlled trial [23].
The aim of the current analysis was to explore whether
patients’ beliefs about their medicine are associated with
the use of a medication list and the memory of medication
counselling and brown bag review.
2. Methods
2.1. Participants. The study took place in the federal state
Baden-Wu¨rttemberg inGermany. Baseline data of all patients
enrolled into the PomP study were analysed. Eligibility
criteria for patients were assessed using insurance claim data
and comprised
(i) age older than 50 years;
(ii) multimorbidity, defined as diagnosis of at least three
chronic conditions based on a previously published
diagnosis list [24];
(iii) polypharmacy, defined as repeated prescription of
more than 4 drugs;
(iv) enrolment in a special care contract of one large
German health insurance (HZV AOK Baden-
Wuerttemberg);
(v) high risk of medication problems according to the
personal assessment of the general practitioner (GP),
for example, nonadherence or previous hospitalisa-
tion due to medication related events.
2.2. Data Collection. The data were collected in October
2013. Patients completed questionnaires on an internet-based
platformon a tablet PC in the practice of their treating general
practitioner, after they had given written informed consent
to participate in the PomP study. The data were stored on a
secure central server of the University of Heidelberg.
The questionnaire included the specific part of the
German version of the Beliefs in Medicines Questionnaire
(BMQ-D) [25] as well as nonvalidated items on the presence
and patients’ use of medication lists, the memory of having
ever receivedmedication counselling and a brown bag review,
and sociodemographic questions.
The BMQ-D has been validated and proved to be suitable
to measure patients’ beliefs in medicine in German primary
care settings [26]. While the general part of the BMQ-D
assesses the beliefs about medicines in general, the specific
part used in this study focuses on patients’ beliefs about
the particular medication prescribed for them. It comprises
two subscales. The “specific-necessity scale” (SNS) assesses
patients’ beliefs about their personal need for the medicine
and how important the medicine is in maintaining their
health now and in the future. The “specific-concerns scale”
(SCS) assesses perceptions about potential negative con-
sequences of taking the medicine [26]. The BMQ-D has
response categories on a five-point Likert scale (1 = strongly
disagree to 5 = strongly agree).
The nonvalidated items onmedication lists were deduced
from previously conducted focus groups (𝑛 = 2), interviews
with medical experts (𝑛 = 26), and patient interviews
(𝑛 = 8). The response categories of these items were partly
dichotomous (yes/no) and partly scaled on a five-point Likert
scale (0 = never to 4 = always).
2.3. Statistical Analysis. All statistical analyses were per-
formed with SPSS, version 21.0 for Windows. For the SNS
and SCS the mean, standard deviation and 95% confidence
interval of the items belonging to the respective scale were
calculated, resulting in a score ranging from one to five,
higher values indicating stronger concerns or stronger per-
ception of necessity, respectively. One item of the SCS was
invalid due to a mistake in the wording. For this scale the
mean of all valid items was calculated. A missing value was
set if a participant had one or more missing values for any of
the included statements.
The correlation between each BMQ-D subscale and
the background variables was calculated using Spearman’s
correlation coefficient or Pearson correlation coefficient,
respectively. Variables with sufficient potential interest (𝑝 <
0.20) as well as the sociodemographic data were included into
two linear regression models and handled as independent
variables. The linear regression analyses were carried out
for the two subscales of BMQ-D, which were treated as
dependent variables. An alpha level of 𝑝 < 0.05 was used for
statistical significance.
3. Results
3.1. Characteristics of the Sample. Table 1 shows the charac-
teristics of the sample. In total, 344 patients completed the
survey. The average age was 72.1 years, and 58% (𝑛 = 198)
of the participants were female. The majority of patients
were not working any more (85%, 𝑛 = 293), living in a
multiperson household (69%, 𝑛 = 238), and having a long-
term relationship (66%, 𝑛 = 226).
The descriptive results of BMQ-D scales, medication lists,
and medication counselling are depicted in Table 2.
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Table 1: Characteristics of the survey respondents (𝑛 = 344).
Characteristics
Age in years; mean (SD) (range) 72.1 (SD 8.94) (52–94)
Female, % (𝑛) 57.6 (198)
Having a long-term relationship, %
(𝑛) 65.7 (226)
Living with other persons, % (𝑛) 69.2 (238)
Not working, % (𝑛) 85.2 (293)
High school or university degree, %
(𝑛) 4.9 (17)
Secondary modern school
qualification, % (𝑛) 76.7 (264)
3.2. Patients’ Beliefs in Medicine. The percentage of missing
values for the BMQ-D SNS was 0% and for the BMQ-D SCS
2.3%.Themean score for the BMQ-D SNSwas 4.34 on a scale
from 1 (strongly disagree) to 5 (strongly agree), reflecting
a general strong belief in the necessity of the medication
actually taken by the patients, whereas the mean score for the
BMQ-D SCS was 2.47 on a scale from 1 (strongly disagree) to
5 (strongly agree), reflecting moderate concerns towards the
prescribed medication.
3.3. Patients’ Use of Their Medication List. As Table 2 shows,
on average patients stated finding the information on their
medication list frequently or always comprehensible (mean
= 3.52) and receiving a new medication list after their
medication was altered frequently or always (mean = 3.63).
Scores were lower for the items referring to the active use of
the medication list by the patients. They stated carrying their
medication list rarely to sometimes with them (mean = 1.64)
and updating their medication list never to rarely (mean =
0.77) when buying an over-the-counter drug. About half of
the patients (50.6%, 𝑛 = 174) considered their medication
list an important reminder and 40% (𝑛 = 146) used it as
aid when administering their medication. About one-third
(30.2%, 𝑛 = 104) stated showing their medication lists during
doctor’s appointments, but only a minority (4.1%, 𝑛 = 14) did
so when buying a drug in the pharmacy.
3.4. Patients’ Memory of Medication Counselling and Brown
BagReview. About two-third of the patients (62.8%, 𝑛 = 216)
remembered an appointment for medication counselling at
their GP, but only one-third stated having brought their
medication packages to this appointment (thus to have
received a “brown bag review”) as recommended.
3.5. Association between Memory of Medication Counselling,
Use of Mediation Lists, and Beliefs in Medicine. Tables 3 and
4 show the results of the linear regression models related
to the BMQ-D SNS or BMQ-D SCS, respectively, both
controlled for sociodemographic data. The items “I usually
show my medication list during doctor’s appointments,” “I
usually show my medication list when buying a drug in the
pharmacy,” and “I usually usemymedication list when taking
my medication” were not included into the regression model
of BMQ-D SNS since 𝑝 > 0.20. Moreover, the items “Do
you receive an updated medication list from your GP if your
medication changes?” and “I usually showmymedication list
when buying a drug in the pharmacy” were not included into
the regression model of BMQ-D SCS since 𝑝 > 0.20.
Regular receipt of an updated medication list was asso-
ciated with higher perceived necessity of the medication,
while the memory of a “brown bag review” was nega-
tively associated with perceived necessity. Patients who had
stronger concerns towards their medication were more likely
to remember a “brown bag review,” to carry their medication
list along and to update their medication list when buying
over-the-counter drugs. Patients who found their medication
list comprehensive had less concerns about their medication.
4. Discussion
In our study patients’ memory of a brown bag review and
the use of a medication list correlated with their beliefs about
their medicine.
The memory of a brown bag review was associated
with stronger concerns and lower perceived necessity about
the medication. This seems to contradict with the general
consensus that medication reviews are valuable instruments
to increase medication safety [27]. The finding suggests
that also potential negative psychological effects of intensive
medication counselling should be considered. This is in line
with the concerns of some doctors to unsettle patients by
giving too detailed information about medicines, especially
about possible side-effects, which we identified as potential
barrier for the implementation of medication counselling in
previous qualitative studies [28, 29].
On the other hand, stronger concerns were associ-
ated with more active patient behaviour. Patients who had
stronger concerns about their medication were more likely
to carry their medication list with them and to add over-
the-counter drugs on the list. This contrasts with the general
assumption that concerns have to be minimized in order
to increase adherence [30] and supports the importance of
addressing patients’ attitudes and feelings towards their med-
ication respecting differences in personalities. Minimising
concerns leading to nonadherence among “anxious” patients
might be just as important as raising awareness for possible
risks of pharmacotherapy among “careless” patients.
Finding this balance might be a challenge for health care
professionals and require special pharmacological knowledge
and conversational skills. In fact, there is little guidance on
what level of detailed medication counselling should be con-
ducted. Checklists for medication counselling usually specify
general conversation topics [20, 22] but do not concretise
the essential information to be given about different types
of drugs. Further research should focus on methods to train
and guide doctors and nurses in medication counselling and
brown bag reviewing. Quality standards for these important
care processes should be developed, for example, by elabo-
rating the essential information that must be conveyed and
collected during medication counselling on the level of the
active ingredients of a medication.
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Table 2: Descriptive results of BMQ-D, medication list, and medication counselling.
Beliefs about medicine∗ Mean SD 95% CI
BMQ-D “specific-necessity scale” 4.34 0.59 4.29–4.41
BMQ-D “specific-concerns scale” 2.47 0.89 2.37–2.57
Use of the medication list∗∗ Mean SD CI
Do you find the information on your medication list comprehensive? 3.63 0.65 3.56–3.71
Do you receive an updated medication list from your GP when your medication
changes?
3.52 0.86 3.42–3.62
Do you discard your previous medication list after receiving a new one? 3.11 1.33 2.96–3.26
Do you carry your medication list with you (e.g., in your purse)? 1.64 1.65 1.45–1.83
Do you note down on your medication list when you have a bought a new drug? 0.77 1.31 0.62–0.92
Use of medication list Yes % (𝑛)
My medication list is an important reminder for me. 50.6 (174)
I usually show my medication list during doctor’s appointments. 30.2 (104)
I usually show my medication list when buying a drug in the pharmacy. 4.1 (14)
I usually use my medication list when taking my medication. 42.4 (146)
Memory of medication counselling and “brown bag review” yes % (𝑛)
Have you ever received “medication counselling” (an appointment, during which
you explicitly talked about your medication) by your general practitioner?
62.8 (216)
If yes, did you bring all medication packages, you are using, to this appointment (so
called “brown bag review”)?
32.0 (110)
∗Beliefs aboutMedicines Questionnaire (BMQ): scores possibly range from 1 to 5, higher values indicating higher perceived necessity or concerns, respectively.
∗∗Items assessing the use of medication lists: scores possibly range from 0 to 4 (0 = never, 4 = always).
Table 3: Associations of individual characteristics, medication list, and medication counselling on BMQ-D “specific-necessity scale.”
𝛽 (𝑝 value)
Do you receive an updated medication list from your GP if your medication changes? 0.286 (<0.01)
If yes, did you bring all medication packages, you are using, to this appointment (so called “brown bag review”)? −0.268 (0.01)
𝑅
2 0.152
Results of stepwise linear regression analysis, under specification of standardized beta coefficient, 𝛼 = 5%. Only the last step and coefficients with statistically
significances at 𝑝 < 0.05 level are reported.
In our study, patients who found their medication
list most comprehensive had less concerns towards their
medication and regular receipt of an updated medication
list was associated with higher perceived necessity of the
medication. This underlines the importance of establishing a
standardized, high-quality medication list and also the need
of empowering patients in the use of it. Therefore we argue
that instructions on how to use medication lists correctly
should be part of medication counselling and included into
respective checklists.
This study has some strengths and limitations, which
should be considered when interpreting results. Beside self-
developed questions we used internationally validated mea-
sures for the evaluation of patient beliefs on medicines.
However, our sample may not be representative for all
patients with multiple chronic conditions and polypharmacy
in Germany, although the age and gender patterns are
comparable to those of a large German cohort study on
multimorbid patients [31]. Moreover, this was an exploratory
study; 𝑝 values should be interpreted only in an explorative
manner and need to be confirmed in further targeted studies.
5. Conclusions
The results of our study indicate that regular receipt of
an updated and comprehensive medication list may reduce
patients’ concerns and increase the perceived necessity of
their medication. This supports the demand to establish
standardized, high-quality medication lists and to instruct
patients in using them. Our findings suggest as well that
potential negative effects of intensive medication counselling
on patients beliefs about their medicine should be taken into
consideration. Consequently, quality standards for the course
and contents of structuredmedication counselling, ideally on
the level of active agents, should be developed.
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Table 4: Associations of individual characteristics, medication list, and medication counselling on BMQ-D “specific-concerns scale.”
𝛽 (𝑝 value)
Do you carry your medication list with you (e.g., in your purse)? 0.224 (<0.01)
Do you find the information on your medication list comprehensive? −0.224 (<0.01)
If yes, did you bring all medication packages, you are using, to this appointment (so called “brown bag review”)? 0.160 (0.02)
Do you note down on your medication list if you have a bought a new drug? 0.156 (0.032)
𝑅
2 0.140
Results of stepwise linear regression analysis, under specification of standardized beta coefficient, 𝛼 = 5%. Only the last step and coefficients with statistically
significances at 𝑝 < 0.05 level are reported.
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